Zobrazeno 1 - 10
of 106
pro vyhledávání: '"G P, La Torre"'
Autor:
Gabriel G. De la Torre, Gernot Groemer, Ana Diaz-Artiles, Nathalie Pattyn, Jeroen Van Cutsem, Michaela Musilova, Wieslaw Kopec, Stefan Schneider, Vera Abeln, Tricia Larose, Fabio Ferlazzo, Pierpaolo Zivi, Alexandra de Carvalho, Gro Mjeldheim Sandal, Leszek Orzechowski, Michel Nicolas, Rebecca Billette de Villemeur, Anne Pavy-Le Traon, Ines Antunes
Publikováno v:
npj Microgravity, Vol 10, Iss 1, Pp 1-16 (2024)
Abstract Space analog research has increased over the last few years with new analogs appearing every year. Research in this field is very important for future real mission planning, selection and training of astronauts. Analog environments offer spe
Externí odkaz:
https://doaj.org/article/e9b22cb10d5c4d02affc0515eca509c7
Autor:
Hlobisile Nzama, Srinivas Rao Manne, Oleg Marder, Gyorgy Orosz, Beatriz G. de la Torre, Fernando Albericio
Publikováno v:
Green Chemistry Letters and Reviews, Vol 17, Iss 1 (2024)
Although N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HCl) is a common reagent in peptide synthesis, it presents two drawbacks. First of all, it is in a tautomerism equilibrium with cyclic form that it is not productive. Secon
Externí odkaz:
https://doaj.org/article/adbd819b867e4545bd2fff0c77dbc9ea
Publikováno v:
International Journal of Adolescence and Youth, Vol 29, Iss 1 (2024)
The presence of meaning in life (MiL) and character strengths (CS) are protective factors for adolescents’ mental health. The main objective of the present study was to explore transculturally the relationship between MiL and CS with anxiety and de
Externí odkaz:
https://doaj.org/article/aea9d69175b54a859dc69cc8c3b0fe15
Publikováno v:
Green Chemistry Letters and Reviews, Vol 17, Iss 1 (2024)
Triethyl phosphate (TEP) is a new member of the Green Solid-Phase Peptide Synthesis (GSPPS) toolbox. TEP shows almost no toxicity and no carcinogenic or mutagenic properties. It degrades, giving the rather innocuous phosphoric acid and ethanol. TEP h
Externí odkaz:
https://doaj.org/article/5c02bbf184374f19944c77f13cec1911
Autor:
Ndumiso Mthethwa, K. P. Nandhini, Ashish Kumar, Anamika Sharma, Beatriz G. de la Torre, Fernando Albericio
Publikováno v:
Green Chemistry Letters and Reviews, Vol 17, Iss 1 (2024)
Solid-phase peptide synthesis (SPPS) is the method of choice for the synthesis of peptides for research and production purposes. Despite having several positive features, it remains a challenge to reduce the amount of solvent waste generated during t
Externí odkaz:
https://doaj.org/article/0889af9756644aeda8f9f661ccbc1e20
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 1992 (2024)
An increase in total drug (small molecules and biologics) approvals by the Food and Drug Administration (FDA) was seen in 2023 compared with the previous year. Cancer remained the disease most targeted by monoclonal antibodies (mAbs), followed by aut
Externí odkaz:
https://doaj.org/article/902e380c36ce4c5db7917634e9859827
Publikováno v:
Advanced Science, Vol 10, Iss 26, Pp n/a-n/a (2023)
Abstract Antimicrobial peptides (AMPs) are essential elements of thehost defense system. Characterized by heterogenous structures and broad‐spectrumaction, they are promising candidates for combating multidrug resistance. Thecombined use of AMPs wi
Externí odkaz:
https://doaj.org/article/15b6379146354c88bbeeca7d004f3ba2
Publikováno v:
Molecules, Vol 29, Iss 7, p 1429 (2024)
Solid-phase peptide synthesis (SPPS) is the preferred strategy for synthesizing most peptides for research purposes and on a multi-kilogram scale. One key to the success of SPPS is the continual evolution and improvement of the original method propos
Externí odkaz:
https://doaj.org/article/a2dba798e30b466fb2a67f9f6f1344eb
Publikováno v:
Pharmaceuticals, Vol 17, Iss 2, p 243 (2024)
A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The four approved oligonucleotides are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary hyperoxa
Externí odkaz:
https://doaj.org/article/4dae35486161477388f8e34c1bc7a62d
Publikováno v:
Molecules, Vol 29, Iss 3, p 585 (2024)
With the COVID-19 pandemic behind us, the U.S. Food and Drug Administration (FDA) has approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best year
Externí odkaz:
https://doaj.org/article/1b0c7f208783402f955c82eb9ed84ddd